Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Secukinumab (Cosentyx) is a newly approved recombinant human monoclonal antibody used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (or both). Secukinumab is administered subcutaneously, either by the patient or a provider.

 

* The most common adverse effects include diarrhea, nasopharyngitis, and upper respiratory infections. Those who receive secukinumab may also have severe allergic reactions and have an increased risk of developing infections.